These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 33497609)

  • 1. In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma.
    Dubrot J; Lane-Reticker SK; Kessler EA; Ayer A; Mishra G; Wolfe CH; Zimmer MD; Du PP; Mahapatra A; Ockerman KM; Davis TGR; Kohnle IC; Pope HW; Allen PM; Olander KE; Iracheta-Vellve A; Doench JG; Haining WN; Yates KB; Manguso RT
    Immunity; 2021 Mar; 54(3):571-585.e6. PubMed ID: 33497609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
    Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
    Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion.
    Freeman AJ; Vervoort SJ; Ramsbottom KM; Kelly MJ; Michie J; Pijpers L; Johnstone RW; Kearney CJ; Oliaro J
    Cell Rep; 2019 Sep; 28(11):2784-2794.e5. PubMed ID: 31509742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient gene disruption in cultured primary human endothelial cells by CRISPR/Cas9.
    Abrahimi P; Chang WG; Kluger MS; Qyang Y; Tellides G; Saltzman WM; Pober JS
    Circ Res; 2015 Jul; 117(2):121-8. PubMed ID: 25940550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
    Dai S; Zhuo M; Song L; Chen X; Yu Y; Zang G; Tang Z
    Immunobiology; 2016 Jul; 221(7):813-21. PubMed ID: 26874581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancements in CRISPR screens for the development of cancer immunotherapy strategies.
    Li YR; Lyu Z; Tian Y; Fang Y; Zhu Y; Chen Y; Yang L
    Mol Ther Oncolytics; 2023 Dec; 31():100733. PubMed ID: 37876793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A versatile modular vector system for rapid combinatorial mammalian genetics.
    Albers J; Danzer C; Rechsteiner M; Lehmann H; Brandt LP; Hejhal T; Catalano A; Busenhart P; Gonçalves AF; Brandt S; Bode PK; Bode-Lesniewska B; Wild PJ; Frew IJ
    J Clin Invest; 2015 Apr; 125(4):1603-19. PubMed ID: 25751063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR genome engineering and viral gene delivery: a case of mutual attraction.
    Schmidt F; Grimm D
    Biotechnol J; 2015 Feb; 10(2):258-72. PubMed ID: 25663455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CFTR inactivation by lentiviral vector-mediated RNA interference and CRISPR-Cas9 genome editing in human airway epithelial cells.
    Bellec J; Bacchetta M; Losa D; Anegon I; Chanson M; Nguyen TH
    Curr Gene Ther; 2015; 15(5):447-59. PubMed ID: 26264708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing.
    Chiou SH; Winters IP; Wang J; Naranjo S; Dudgeon C; Tamburini FB; Brady JJ; Yang D; Grüner BM; Chuang CH; Caswell DR; Zeng H; Chu P; Kim GE; Carpizo DR; Kim SK; Winslow MM
    Genes Dev; 2015 Jul; 29(14):1576-85. PubMed ID: 26178787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy.
    Odegard JM; Kelley-Clarke B; Tareen SU; Campbell DJ; Flynn PA; Nicolai CJ; Slough MM; Vin CD; McGowan PJ; Nelson LT; Ter Meulen J; Dubensky TW; Robbins SH
    J Immunother; 2015; 38(2):41-53. PubMed ID: 25658613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening.
    Joung J; Konermann S; Gootenberg JS; Abudayyeh OO; Platt RJ; Brigham MD; Sanjana NE; Zhang F
    Nat Protoc; 2017 Apr; 12(4):828-863. PubMed ID: 28333914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of HLA-G for protection of human renal cell-carcinoma cells from immune-mediated lysis: implications for immunotherapies.
    Bukur J; Seliger B
    Semin Cancer Biol; 2003 Oct; 13(5):353-9. PubMed ID: 14708715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene.
    Hernández JM; Bui MH; Han KR; Mukouyama H; Freitas DG; Nguyen D; Caliliw R; Shintaku PI; Paik SH; Tso CL; Figlin RA; Belldegrun AS
    Clin Cancer Res; 2003 May; 9(5):1906-16. PubMed ID: 12738749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphocyte therapy of renal cell carcinoma.
    Dillman RO
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):1041-51. PubMed ID: 16336095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational Discovery of Cancer Immunotherapy Targets by Intercellular CRISPR Screens.
    Yim S; Hwang W; Han N; Lee D
    Front Immunol; 2022; 13():884561. PubMed ID: 35651625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy.
    Li Y; Yang C; Liu Z; Du S; Can S; Zhang H; Zhang L; Huang X; Xiao Z; Li X; Fang J; Qin W; Sun C; Wang C; Chen J; Chen H
    Mol Cancer; 2022 Jan; 21(1):2. PubMed ID: 34980132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation.
    Moreno AM; Fu X; Zhu J; Katrekar D; Shih YV; Marlett J; Cabotaje J; Tat J; Naughton J; Lisowski L; Varghese S; Zhang K; Mali P
    Mol Ther; 2018 Jul; 26(7):1818-1827. PubMed ID: 29754775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radio frequency ablation combined with interleukin-2 induces an antitumor immune response to renal cell carcinoma in a murine model.
    Kroeze SG; Daenen LG; Nijkamp MW; Roodhart JM; de Gast GC; Bosch JL; Jans JJ
    J Urol; 2012 Aug; 188(2):607-14. PubMed ID: 22704448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.
    Dubrot J; Du PP; Lane-Reticker SK; Kessler EA; Muscato AJ; Mehta A; Freeman SS; Allen PM; Olander KE; Ockerman KM; Wolfe CH; Wiesmann F; Knudsen NH; Tsao HW; Iracheta-Vellve A; Schneider EM; Rivera-Rosario AN; Kohnle IC; Pope HW; Ayer A; Mishra G; Zimmer MD; Kim SY; Mahapatra A; Ebrahimi-Nik H; Frederick DT; Boland GM; Haining WN; Root DE; Doench JG; Hacohen N; Yates KB; Manguso RT
    Nat Immunol; 2022 Oct; 23(10):1495-1506. PubMed ID: 36151395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.